Viking Shares New VK2735 Data, Reports BMI And Metabolic Improvements After 13 Weeks
Viking Therapeutics (VKTX) presented data from its obesity drug VK2735 at ObesityWeek 2026. Phase 2 results showed 74% of participants improved BMI after 13 weeks, with significant metabolic benefits. Phase 3 trials are ongoing, with completion expected in 2027. The stock closed at $29.22, up 5.95%.
How this was made

The 30-second read
Why it matters
The data suggest a strong efficacy signal that could accelerate the path to Phase 3 and eventual market entry, influencing valuation.
Market read
First‑time disclosure of robust Phase 2 results for an obesity drug, a high‑impact catalyst for a small‑cap biotech.
What to watch
Potential competition from other GLP‑1/GIP combos and reimbursement uncertainty.
Background
Viking Therapeutics presented new Phase 2 data at ObesityWeek 2026, highlighting BMI category improvements and weight loss outcomes.
Ticker impact
VKTX disclosed Phase 2 obesity trial data showing significant BMI category improvements and weight loss after 13 weeks.
likely upside as the market prices in the encouraging efficacy and safety data
Phase 2 data with strong efficacy signals historically lift biotech stocks, especially when safety is favorable.
Market effects
obesity‑treatment biotech sector may see broader interest and valuation uplift.
U.S. biotech market could benefit from renewed investor confidence.
global obesity drug pipeline may attract attention from international investors.
Counterpoint
If the data do not translate into Phase 3 success, the rally could be short‑lived.
Key entities
- companyViking Therapeutics, Inc.
Biotech company developing VK2735 for obesity and metabolic disease.



